MEDSIR will present new findings from the ZZ-FIRST study at ASCO 2026, contributing to ongoing scientific conversations in genitourinary oncology and investigator-driven clinical research.
The oral presentation will feature results from a phase II study led by Joaquín Mateo, MD, PhD, at Vall d’Hebron Institute of Oncology (VHIO), exploring intensified treatment strategies in advanced hormone-sensitive prostate cancer.
FINAL RESULTS FROM ZZ-FIRST:
a randomized phase II trial of enzalutamide and talazoparib in metastatic hormone-naïve
prostate cancer
ZZ-FIRST explores the potential of treatment intensification through the combination of PARP inhibition and androgen receptor (AR) blockade in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
The study evaluates whether the addition of talazoparib to enzalutamide and androgen deprivation therapy may improve clinical outcomes, while advancing the understanding of early tumor adaptation, treatment response and resistance to androgen receptor pathway inhibition through translational analyses conducted during the initial phases of treatment.
Previously investigated in more advanced disease stages, this therapeutic combination is now being explored earlier in the metastatic setting, representing a novel approach in hormone-sensitive prostate cancer and reflecting MEDSIR’s continued commitment to investigator-driven research designed to address meaningful clinical questions in oncology.
-
Phase II randomized clinical trial
-
54 patients enrolled
-
Conducted across 8 Spanish sites
-
Focused on high-volume mHNPC
-
Strong translational research included
-
Led by Joaquín Mateo, MD, PhD (VHIO)
Key study highlights
At MEDSIR, investigator-driven research begins with clinically meaningful questions.
By connecting leading investigators, translational science, and strategic development expertise, MEDSIR helps transform innovative oncology concepts into impactful clinical research initiatives.
ASCO 2026 represents another opportunity to contribute to the future of precision oncology through collaborative, scientifically rigorous research.
RESEARCH DESIGNED TO MOVE ONCOLOGY CONVERSATIONS FORWARD
EXPANDING MEDSIR’S ONCOLOGY RESEARCH PIPELINE
The CADILLAC study evaluates a next-generation endocrine-based strategy combining an oral SERD (camizestrant) with CDK4/6 inhibition (ribociclib) in patients with HR-positive/HER2-negative advanced breast cancer.
The study explores whether this approach can serve as an optimized endocrine partner for ribociclib in patients heavily pre-treated with endocrine therapy in earlier settings.
CADILLAC (TiP)
Camizestrant plus ribociclib in
HR-positive/HER2-negative advanced breast cancer
ADELA investigates a targeted combination strategy for patients with ER-positive/HER2-negative advanced breast cancer harboring ESR1 mutations, a key driver of endocrine resistance after progression on prior standard treatment.
By combining an oral SERD (elacestrant) with mTOR inhibition (everolimus), the study explores a potential approach to restore endocrine sensitivity and improve outcomes in a population with limited post–CDK4/6 inhibitor treatment options.
ADELA (TiP)
Elacestrant plus everolimus in
ESR1-mutated advanced
breast cancer
WHY MEDSIR ?
MEDSIR helps pharma, biotech and research partners transform complex oncology development challenges into executable clinical strategies.
By combining scientific understanding, adaptive trial thinking and international operational capabilities, MEDSIR supports programs designed to generate meaningful evidence in highly demanding research settings.
Smarter trial design
Adaptive, science-driven approaches tailored to complex oncology development challenges and emerging therapeutic landscapes.
Global execution
International investigator networks and operational expertise supporting multicenter oncology research across global scientific communities.
Scientific partnership mindset
From early concept development to global scientific presentation, MEDSIR works as a collaborative partner focused on long-term research impact.
CONNECT WITH OUR TEAM
Interested in learning more about ZZ-FIRST, CADILLAC, ADELA or MEDSIR’s broader oncology research initiatives?
Complete the form to connect with our team and continue the conversation around investigator-driven clinical research, scientific collaboration and future development opportunities.
MEDSIR representatives will also be attending ASCO 2026 in Chicago and would be pleased to connect during the congress.
ABOUT MEDSIR
MEDSIR is an international oncology research company focused on the development of innovative and strategic clinical trials.
By combining medical, scientific and operational excellence, MEDSIR helps pharma, biotech and research stakeholders translate bold ideas into meaningful clinical development paths.
UNDER THE
STANDARDS OF:
© 2025 MEDSIR | PRIVACY POLICY | LEGAL NOTICE | OFFICIAL NOTICE | COOKIE POLICY | QUALITY POLICY | INFORMATION SECURITY | CONVIVECONELCANCER - MEDSIR FOR PATIENTS |
INFO@MEDSIR.ORG Pere IV 128 3rd Floor, Barcelona, Spain, 08005.